Lineage Cell Therapeutics, Inc.
LCTX· NYSE
LCTXLineage Cell Therapeutics, Inc.
Filed May 10, 2013 · 10-Q · 40 days after period end · 0001140361-13-020144
| Metric | Q1 2013 | Q1 2012 | Q1 2011 |
|---|---|---|---|
| Revenue | $431.72K | $631.95K | $824.63K |
| Net Income | -$7.72M | -$4.97M | -$3.36M |
| EPS Diluted | -$0.15 | -$0.10 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
ended Mar 31, 2013 · filed May 10, 2013 · 40 d after period end
